Lacidipine Zentiva (Lacidipine)

Lacidipine selectively blocks L‑type calcium channels on vascular smooth‑muscle cells. This inhibition reduces calcium entry, causing arterial vasodilation, decreasing peripheral vascular resistance, and ultimately lowering systolic and diastolic blood pressure without significant negative effects on heart contractility.

The appropriate dose of Lacidipine Zentiva is determined by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Safety data for lacidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lacidipine belongs to the dihydropyridine calcium‑channel blocker class, which primarily causes arterial vasodilation. Compared with ACE inhibitors or ARBs, it has a more pronounced effect on peripheral resistance and may cause flushing or edema, while offering similar blood‑pressure‑lowering efficacy.

Lacidipine Zentiva tablets should be stored at room temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat, and direct sunlight to maintain product stability throughout its shelf life.

Lacidipine Zentiva is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split unless specifically instructed.

Serious risks include severe hypotension, myocardial infarction, hepatic injury, and rare allergic reactions such as anaphylaxis or angio‑edema. Patients should seek immediate medical attention if they experience sudden dizziness, chest pain, jaundice, or swelling of the face and throat.

Lacidipine Zentiva is contraindicated in patients with known hypersensitivity to lacidipine or any component of the formulation, and in individuals with severe aortic stenosis or unstable angina. Caution is also advised for patients with significant liver disease or those taking interacting medications.